Rajthanee Hospital vs Encompass Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Rajthanee Hospital Public Company Limited (RJH.BK)

Q3 202620 Aug – 8 Oct 2026

▲4

RJH rides social security growth and fee hopes to strong Q3

Social security patient base beats target early RJH's insured patient count hit 261,000, ahead of its end-2026 goal, with more surgical cases. This boosts patient volume and revenue, supporting profit growth and a DBS buy call with an 18.60 baht target.
Shows a key demand driver that directly lifts RJH's revenue and earnings.
Q2 profit surge stands out in weak hospital sector RJH's Q2 net profit jumped about 80-89% to 113 million baht, far outpacing peers like BDMS and BH. This strong result shows company-specific strength and supports the stock's valuation.
Highlights RJH's exceptional earnings growth versus a sluggish sector, a clear positive for the stock.
Cabinet expands social security coverage, boosting demand The Cabinet approved adding 550,000 insured people in 2026, rising to 1.05 million by 2030. With 53% of RJH's revenue from social security, this expands its patient pool and long-term revenue potential.
A regulatory change that increases RJH's addressable patient base, directly supporting future revenue.
Brokers see SSO fee hike as major profit catalyst The Social Security Office is reviewing per-head payments, with a decision due by Oct 24. A 1% rise could lift RJH's profit by 3.1%, and a 5% rise by 15.3%. Kasikorn and Yuanta see upside, with Kasikorn raising its target to 17.70 baht.
A pending regulatory decision that could significantly boost RJH's profits and has driven recent analyst upgrades.

September 202620 Aug – 8 Oct 2026

▲4

RJH rides social security growth and fee hopes to strong Q3

Social security patient base beats target early RJH's insured patient count hit 261,000, ahead of its end-2026 goal, with more surgical cases. This boosts patient volume and revenue, supporting profit growth and a DBS buy call with an 18.60 baht target.
Shows a key demand driver that directly lifts RJH's revenue and earnings.
Q2 profit surge stands out in weak hospital sector RJH's Q2 net profit jumped about 80-89% to 113 million baht, far outpacing peers like BDMS and BH. This strong result shows company-specific strength and supports the stock's valuation.
Highlights RJH's exceptional earnings growth versus a sluggish sector, a clear positive for the stock.
Cabinet expands social security coverage, boosting demand The Cabinet approved adding 550,000 insured people in 2026, rising to 1.05 million by 2030. With 53% of RJH's revenue from social security, this expands its patient pool and long-term revenue potential.
A regulatory change that increases RJH's addressable patient base, directly supporting future revenue.
Brokers see SSO fee hike as major profit catalyst The Social Security Office is reviewing per-head payments, with a decision due by Oct 24. A 1% rise could lift RJH's profit by 3.1%, and a 5% rise by 15.3%. Kasikorn and Yuanta see upside, with Kasikorn raising its target to 17.70 baht.
A pending regulatory decision that could significantly boost RJH's profits and has driven recent analyst upgrades.

Latest20 Aug – 8 Oct 2026

▲4

RJH rides social security growth and fee hopes to strong Q3

Social security patient base beats target early RJH's insured patient count hit 261,000, ahead of its end-2026 goal, with more surgical cases. This boosts patient volume and revenue, supporting profit growth and a DBS buy call with an 18.60 baht target.
Shows a key demand driver that directly lifts RJH's revenue and earnings.
Q2 profit surge stands out in weak hospital sector RJH's Q2 net profit jumped about 80-89% to 113 million baht, far outpacing peers like BDMS and BH. This strong result shows company-specific strength and supports the stock's valuation.
Highlights RJH's exceptional earnings growth versus a sluggish sector, a clear positive for the stock.
Cabinet expands social security coverage, boosting demand The Cabinet approved adding 550,000 insured people in 2026, rising to 1.05 million by 2030. With 53% of RJH's revenue from social security, this expands its patient pool and long-term revenue potential.
A regulatory change that increases RJH's addressable patient base, directly supporting future revenue.
Brokers see SSO fee hike as major profit catalyst The Social Security Office is reviewing per-head payments, with a decision due by Oct 24. A 1% rise could lift RJH's profit by 3.1%, and a 5% rise by 15.3%. Kasikorn and Yuanta see upside, with Kasikorn raising its target to 17.70 baht.
A pending regulatory decision that could significantly boost RJH's profits and has driven recent analyst upgrades.

Encompass Health Corp (EHC)

Q3 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

August 20261 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.

Latest1 Aug – 24 Sep 2026

▲3

EHC beats and raises again, adds capacity as Medicare rates rise

Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.
The earnings beat and raised outlook are the core new fundamental driver of the stock.
Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.
A regulatory rate change directly raises EHC's reimbursement and future revenue.
Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.
New hospital projects show how EHC plans to grow revenue beyond current guidance.
Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.
This is the real counterweight: insider selling and leverage could hold the stock back.